Investment Pitches

Pitch Summary:
Natera is a specialty diagnostics laboratory that provides high-value genetic testing across three core franchises: reproductive health, oncology led by Signatera, and transplant monitoring. These tests are built on the company’s proprietary cell-free DNA liquid biopsy platform, enabling highly sensitive detection from a blood sample. Shares contributed positively after the company reported strong fiscal third-quarter earnings, with management commentary pointing to revenue and margin performance that exceeded expectations on the back of higher test volumes and favorable reimbursement dynamics—particularly within the Signatera franchise—alongside another increase to full-year 2025 revenue and margin guidance.

BSD Analysis:
Natera is evolving from a prenatal testing leader into a broader precision medicine platform anchored by Signatera in oncology. The recurring-use nature of minimal residual disease testing improves lifetime value versus one-off diagnostics. Clinical adoption is accelerating faster than reimbursement normalization, creating near-term margin pressure. Gross margins are improving as scale builds, but profitability remains a medium-term goal. Natera’s data advantage is becoming a moat as longitudinal datasets grow. The upside hinges on Signatera becoming standard of care. This is a category-defining diagnostics company still early in its earnings curve.

Pitch Summary:
Guardant Health is a molecular diagnostics company specializing in liquid biopsy tests for oncology applications. Unlike traditional tissue-based tests, Guardant’s liquid biopsies use blood samples, enabling faster results and improved patient comfort. The company’s tests include comprehensive genomic profiling, cancer diagnosis, and treatment monitoring. Shares contributed to performance after the company delivered strong fiscal third-quarter operating results and raised full-year 2025 revenue guidance, signaling stronger-than-expected momentum across Oncology, Screening, and Biopharma & Data.

BSD Analysis:
Guardant is a pioneer in liquid biopsy, enabling cancer detection and monitoring through blood-based genomic testing. Its strength lies in oncology, where longitudinal monitoring and treatment selection drive repeat testing. Gross margins are improving, but cash burn remains elevated as the company invests ahead of scale. Clinical validation continues to expand Guardant’s relevance across cancer types. Competition is intense, but Guardant’s data depth and physician adoption remain advantages. Reimbursement expansion is the key catalyst. This is a high-growth oncology diagnostics name still proving economic durability.

Pitch Summary:
Exact Sciences is a molecular diagnostics company focused on oncology testing, best known for its Cologuard noninvasive colorectal cancer screening franchise, alongside a broader portfolio and pipeline that includes molecular residual disease (MRD) and multi-cancer early detection (MCED) testing initiatives. Shares contributed positively during the quarter after Abbott announced a definitive all-cash agreement to acquire Exact Sciences for approximately $21 billion in equity value, reflecting a meaningful premium and driving the stock higher.

BSD Analysis:
Exact Sciences built its franchise on Cologuard, turning non-invasive cancer screening into a mainstream clinical tool. The long-term opportunity lies in expanding beyond colorectal cancer into multi-cancer screening and blood-based diagnostics. Revenue growth remains solid, but profitability is still constrained by heavy R&D and commercialization spend. The company’s clinical credibility and payer coverage create real barriers to entry. Execution risk centers on converting scientific promise into scalable, reimbursed products. If operating leverage finally kicks in, earnings power changes quickly. This is a diagnostics platform still transitioning from growth story to business discipline.

Pitch Summary:
Meta is the world’s largest social-media company, operating platforms that include Facebook, Instagram, WhatsApp, and Messenger. Shares detracted during the quarter as investors focused on guidance for materially higher operating expenses and capital expenditures tied to AI infrastructure investments. Management indicated that 2026 capital expenditures would be notably higher, pressuring forward earnings expectations. This overshadowed continued advertising momentum and management commentary suggesting revenue growth could remain robust into year-end.

BSD Analysis:
Meta has reasserted itself as the most efficient digital advertising engine in the world. AI-driven recommendation systems have reignited engagement across Facebook and Instagram. Cost discipline has dramatically improved margins and free cash flow. Reels monetization continues to close the gap with legacy formats. Reality Labs remains a long-term option rather than the core thesis. Regulatory and competitive threats persist but haven’t dented ad demand. Meta is once again a cash machine with optional upside.

Pitch Summary:
Microsoft is a beneficiary of corporate America’s transformative digitization. The company operates across Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. Shares detracted during the quarter after Azure growth and forward guidance fell short of elevated investor expectations due to capacity constraints and revenue recognition timing. Azure still grew 39% year-over-year, while commercial bookings surged and remaining performance obligations increased significantly. Management signaled a substantial step-up in capital expenditures to address backlog and support AI workloads.

BSD Analysis:
Microsoft is the central operating system of enterprise AI, embedding intelligence across Azure, Office, GitHub, and security products. Azure continues to benefit from AI workloads and enterprise cloud migration. Copilot introduces a powerful ARPU expansion lever rather than relying on seat growth. The ecosystem’s breadth creates unmatched distribution and stickiness. Margins remain exceptional despite heavy investment. Regulatory noise is manageable given Microsoft’s enterprise positioning. This is the cleanest large-cap AI compounder.

Pitch Summary:
Nebius is a provider of AI-focused cloud infrastructure, operating GPU compute capacity across Europe and expanding in the United States. The company is a differentiated “neocloud” beneficiary of accelerating AI adoption, as demand for high-quality GPU compute continues to outstrip available supply of chips, power, and data center capacity. Nebius operates first-party data centers and has expanded capacity through new U.S. deployments. Shares detracted during the quarter amid a broader selloff in AI infrastructure equities as investors questioned the durability of AI spending. Despite volatility, Nebius continues to sign large, long-term agreements with tier-one customers, improving revenue visibility as new capacity comes online.

BSD Analysis:
Nebius is emerging as a Europe-based AI infrastructure and cloud-services provider, positioning itself as a regional alternative to U.S. hyperscalers. Its focus on AI-native compute and data services targets a fast-growing, underpenetrated market. Capital intensity is high, and profitability is not near-term. Strategic relevance and sovereignty concerns support customer interest. Execution speed and customer acquisition will determine long-term viability. The upside lies in being early to regional AI infrastructure buildout. This is infrastructure optionality with real risk.

Pitch Summary:
Cidara Therapeutics is a biotechnology company developing drug-Fc conjugate therapeutics, with its lead program CD388 designed to prevent influenza infection in high-risk populations. CD388 advanced into the Phase 3 ANCHOR study following compelling Phase 2b NAVIGATE results. The program is positioned as a potentially first-in-class, single-dose prophylactic option for influenza prevention. Shares contributed positively after Merck announced an all-cash agreement to acquire Cidara for approximately $9.2 billion.

BSD Analysis:
Cidara is a clinical-stage biotech focused on long-acting antiviral and antifungal therapies using its Cloudbreak platform. The strategy is to replace chronic dosing with single or infrequent administrations. This approach could materially improve adherence and outcomes in vulnerable patient populations. Clinical data remains early, making valuation highly sensitive to trial results. Partnerships help offset funding risk, but dilution remains a reality. If efficacy is validated, the commercial potential is significant. This is a high-risk, science-driven optionality play.

Pitch Summary:
Natera is a specialty diagnostics laboratory that provides high-value genetic testing across three core franchises: reproductive health, oncology led by Signatera, and transplant monitoring. These tests are built on the company’s proprietary cell-free DNA liquid biopsy platform, enabling highly sensitive detection from a blood sample. Shares contributed positively after the company reported strong fiscal third-quarter earnings, with management commentary pointing to revenue and margin performance that exceeded expectations. Results were driven by higher test volumes and favorable reimbursement dynamics, particularly within the Signatera franchise. Management also raised full-year 2025 revenue and margin guidance again.

BSD Analysis:
Beyond prenatal testing, Natera’s long-term value increasingly rests on oncology surveillance and transplant monitoring. Signatera’s ability to track disease recurrence in real time creates new clinical workflows, not just one-off tests. This recurring-use model improves lifetime customer value. While losses persist, incremental margins are moving in the right direction. Clinical adoption is outpacing reimbursement expansion, which remains a key catalyst. Competition exists, but Natera’s data depth is a moat. This is a platform-in-the-making, not just a diagnostics vendor.

Pitch Summary:
Alphabet is the parent of Google and a global leader in digital advertising, cloud computing, and AI-driven consumer services. Shares contributed positively during the quarter as investors increasingly recognized improving execution across the company’s AI strategy, supported by strong engagement trends and rising AI-related workloads. Google Cloud was a key driver, with management highlighting accelerating usage, including increased AI token processing and continued momentum in the Gemini ecosystem. Sentiment was further supported by strengthening cloud demand and new customer wins, as well as reports that Google may broaden access to its TPU capabilities, including potential deployments beyond Google Cloud.

BSD Analysis:
Alphabet remains one of the most powerful cash-flow machines ever built, anchored by Search and YouTube. AI integration is enhancing ad relevance and monetization rather than cannibalizing core economics. Google Cloud is now a legitimate profit contributor, adding diversification beyond advertising. Regulatory pressure is constant, but user behavior has not shifted. The balance sheet supports aggressive buybacks alongside massive AI investment. Alphabet trades as if disruption is inevitable, but evidence suggests evolution instead. A dominant platform still compounding quietly.

Pitch Summary:
Kratos Defense & Security Solutions is a defense technology company focused on affordable unmanned systems, hypersonics and rocket systems, and satellite command-and-control, which we believe are increasingly aligned with U.S. and allied priorities around rapid fielding and scalable production. Kratos has invested deliberately in parts of the defense supply chain that we believe are increasingly critical to modern warfare and are now reaching an inflection point. While the company reported strong fiscal third-quarter operating results, shares detracted after management’s fiscal fourth-quarter revenue outlook and free-cash-flow expectations came in below analyst estimates. Sentiment was further pressured by delayed cash receipts tied to the U.S. government shutdown and ongoing cost headwinds from legacy unmanned contracts.

BSD Analysis:
Kratos focuses on next-generation defense systems, particularly unmanned platforms, hypersonics, and satellite communications. Its value proposition centers on affordable, attritable systems rather than traditional big-ticket hardware. Defense budgets increasingly favor exactly this type of capability. Revenue growth can be lumpy due to program timing, but backlog visibility is improving. Kratos reinvests heavily, keeping margins suppressed in the near term. If programs scale, operating leverage is significant. This is a future-of-defense technology play with patience required.

Pitch Summary:
AAR Corp. is a global aerospace and defense aftermarket services provider that supports commercial airlines and government customers through parts distribution and supply-chain solutions, as well as maintenance, repair, and overhaul services—an area we believe is structurally supported by high aircraft utilization and an aging fleet. During the quarter, shares detracted from performance amid investor uncertainty following the company’s early-December announcement of a Chief Financial Officer transition; however, we believe underlying demand trends across AAR’s end markets remain healthy.

BSD Analysis:
AAR provides aviation services spanning parts distribution, maintenance, and supply-chain support for commercial and government customers. As global flight hours normalize, aftermarket demand continues to recover. AAR’s value lies in inventory availability, certification expertise, and long-standing customer relationships. Government and defense contracts add stability during commercial aviation downturns. Margins are modest but improving with scale and utilization. Capital intensity is manageable relative to peers. This is a steady aviation recovery play rather than a pure aerospace growth bet.

Pitch Summary:
FirstService provides property and commercial building services through two segments: FirstService Residential, which offers residential property management services across North America, and FirstService Brands, which serves residential and commercial customers through franchise systems and company-owned operations. Shares detracted during the quarter as the market focused on weakness in the more cyclical Brands businesses—particularly restoration and roofing—where management cited tempered activity and a cautious outlook. That concern was reinforced on the third-quarter earnings call, when results were in line on earnings but light on revenue, and management pointed to weather-related and broader commercial macro headwinds weighing on the Brands segment and likely persisting into the next quarter, pressuring the stock despite relative resilience in Residential.

BSD Analysis:
FirstService is a defensive compounder built around essential property services — residential management, restoration, and maintenance. Its operating companies benefit from recurring demand tied to housing stock rather than transaction volumes. Decentralized operations keep incentives aligned while scale improves procurement and systems. Growth comes from steady M&A and organic expansion in fragmented markets. Margins are stable and cash flow reliable across cycles. The business quietly compounds regardless of housing sentiment. A high-quality, underappreciated services platform.

Pitch Summary:
Glaukos is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for glaucoma, corneal disorders, and retinal diseases. Shares contributed positively after the company reported strong fiscal third-quarter results, as revenue growth accelerated to approximately 37% year-over-year, driven by momentum in iDose, its flagship glaucoma product. The company also disclosed U.S. Food & Drug Administration (FDA) approval of its next-generation corneal health product, Epioxa, and indicated initial pricing was set materially above expectations, which was viewed as an incremental growth driver alongside the iDose ramp.

BSD Analysis:
Glaukos pioneered micro-invasive glaucoma surgery, creating an entirely new treatment category. Adoption is driven by demographic trends, physician familiarity, and improving reimbursement dynamics. The company continues expanding its product portfolio beyond early-generation stents. Growth has been strong, but margins lag as R&D and commercialization investment remain heavy. Over time, scale and mix shift should drive operating leverage. Competition is rising, but Glaukos still owns category credibility. This is a medtech innovator transitioning from disruption to platform economics.

Pitch Summary:
Acadia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines that address unmet needs in central nervous system (CNS) disorders. Its products include Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, and Daybue, for Rett syndrome—a rare genetic disorder that affects brain development in children. Shares contributed positively during the quarter after the company reported better-than-expected third-quarter 2025 results that reinforced momentum across its two commercial franchises: Nuplazid saw solid demand and new patient activity, while Daybue posted strong referral trends. Sentiment was further supported late in the quarter by the FDA’s approval of DAYBUE STIX, a new powder formulation, underscoring continued franchise investment.

BSD Analysis:
ACADIA is a CNS-focused biopharma anchored by Nuplazid, with growing emphasis on mood disorders and neuropsychiatric conditions. The company is working to diversify beyond a single-asset narrative through pipeline development and lifecycle management. Commercial execution has been uneven, but cash flow supports continued R&D investment. CNS drug development carries higher clinical risk, but successful differentiation commands premium pricing. ACADIA’s value hinges on pipeline readouts and label expansion. It’s no longer a pure binary biotech, but visibility is still limited. A mid-risk CNS growth story with optionality.

Pitch Summary:
Natera is a specialty diagnostics laboratory that provides high-value genetic testing across three core franchises: reproductive health (including non-invasive prenatal testing for chromosomal conditions such as trisomy 13, 18, and 21), oncology (led by Signatera, which measures circulating tumor DNA to assess treatment response and detect molecular residual disease and cancer recurrence), and transplant (tests used to monitor organ rejection). These tests are built on the company’s proprietary cell-free DNA liquid biopsy platform, enabling highly sensitive detection from a blood sample. Shares contributed positively after the company reported strong fiscal third-quarter earnings, with management commentary pointing to revenue and margin performance that exceeded expectations on the back of higher test volumes and favorable reimbursement dynamics—particularly within the Signatera franchise—alongside another increase to full-year 2025 revenue and margin guidance.

BSD Analysis:
Natera is a leader in cell-free DNA testing, with flagship products in non-invasive prenatal testing and oncology monitoring. Its Signatera platform is becoming a standard tool for detecting minimal residual disease, expanding Natera beyond diagnostics into longitudinal cancer management. Gross margins are improving as volumes scale, though profitability remains a work in progress. Clinical data continues to reinforce the platform’s value, driving adoption among oncologists. Reimbursement and test mix are the main swing factors. Natera is evolving from a testing company into a data-rich precision medicine platform. High growth, but still execution-sensitive.

Pitch Summary:
MDxHealth (MDXH) is a prostate cancer diagnostics screening company we initially purchased at around $2 per share a year ago. Prostate cancer is the second most diagnosed cancer overall and the most common in men. The company’s portfolio includes Exo DX, Confirm mdx, Genomic Prostate Score (GPS), and a hereditary prostate cancer test, supported by a network of over 7,000 physicians and more than 250,000 completed tests. MDXH grew revenue at over 20% in each of the last 12 quarters through Q2 2025 and recently acquired an additional prostate test that could further accelerate growth. The stock declined in November due to confusion around 2026 growth expectations, which we believe was overdone. Despite continued momentum, the stock trades at roughly 2x EV/revenue versus peers at 5–9x for similar growth and margin profiles.

BSD Analysis:
MDxHealth is a molecular diagnostics company focused on improving prostate cancer detection and risk stratification. Its tests aim to reduce unnecessary biopsies while identifying clinically significant cancer earlier. Adoption is driven by physician education and reimbursement expansion rather than pure volume growth. The addressable market is large, but commercialization execution remains the gating factor. Cash burn and capital raises are ongoing concerns, making scale and payer traction critical. If test utilization inflects meaningfully, operating leverage is substantial. This is a clinical-value story still proving commercial durability.

Pitch Summary:
Axsome Therapeutics Inc. (AXSM) was a new addition to investor portfolios in January of 2025 and has been a positive contributor since. Axsome is a biopharmaceutical company focused on central nervous system conditions such as Alzheimer’s Disease Agitation, Major Depressive Disorder, Migraines, and Fibromyalgia. Their products target serious conditions impacting over 150 million people in the United States. Axsome has four products commercially available today with two others in late stages of approval, representing over $16 billion in potential peak sales versus $630 million of revenue in 2025. Auvelity, approved in August 2022 for major depressive disorder, exceeded $500 million in sales in 2025. During Q4 2025, Axsome filed for a label expansion for Alzheimer’s Disease Agitation and received accelerated FDA review. We believe Auvelity alone could reach $2 billion in peak sales for this indication, with approval expected by mid-year, and view the company as a potential acquisition target.

BSD Analysis:
Axsome is a commercial-stage biopharma with approved CNS drugs and a pipeline targeting high-unmet-need indications. Revenue growth is accelerating as new launches gain traction. The market opportunity in depression, migraine, and sleep disorders is massive. Execution risk exists around commercialization spend and reimbursement. Unlike many biotechs, Axsome has real products on the shelf. Pipeline readouts add optionality beyond current revenues. This is a growth biotech transitioning from story to substance.

Pitch Summary:
Mama’s Creations (MAMA) was a strong performer for the portfolio throughout 2025. MAMA markets, manufactures, and distributes ready-to-eat deli style packaged food products. Their products include beef meatballs, turkey meatballs, beef meat loaf, sausage and peppers, chicken parmesan, and other similar meats and sauces. Shoppers are increasingly looking for ready-to-eat food options at grocery and convenience stores with a focus on cleaner, protein items with simple ingredients. We originally purchased Mama shares at $2.50 and $3.50 and added more at $7.00 and $11.00 per share. The company has a new CEO, Adam Michaels, who has previously worked at Mondelez International. Since Adam joined the company in September of 2022, management has improved multiple operational processes within the business, driving margins and growth. Mama’s has over 45,000 product placements and recently won national placements at Walmart, Target, and Costco, each of which could become $100 million customers over time. Management believes the company can achieve $1 billion in revenue by 2030, up from approximately $170 million expected in 2025.

BSD Analysis:
Mama’s Creations is a fast-growing refrigerated foods brand benefiting from demand for fresh, premium convenience meals. Its products resonate with health-conscious consumers seeking alternatives to frozen or shelf-stable options. Distribution expansion is the main growth driver. Margins are improving as scale builds and procurement normalizes. Execution risk lies in managing growth without sacrificing quality. The brand has early momentum but remains small. This is a niche consumer-growth story with real upside if scale economics materialize.

Pitch Summary:
Sprott Inc. is a leading global precious metals asset manager that provides investors with access to physical precious metals, mining equities and critical materials across the entire mining lifecycle. A key competitive advantage is Sprott’s physical trust structure, which is fully backed by physical metal, allows for physical redemption, and benefits from trusted custody arrangements such as the Royal Canadian Mint. During periods of market stress, Sprott has consistently gained market share, as evidenced by substantial inflows into its physical gold and silver trusts while competing ETFs experienced large outflows. The firm has also established a dominant position in uranium through the Sprott Physical Uranium Trust, effectively becoming the institutional gateway for uranium exposure. Assets under management have grown to approximately US$50 billion from US$17 billion five years ago, creating significant operating leverage and free cash flow expansion. We believe Sprott offers leveraged exposure to rising commodity prices while avoiding the operational risks inherent in mining, positioning it as a toll collector in a sustained commodity upcycle.

BSD Analysis:
Sprott is a specialist asset manager with deep credibility in real assets, particularly precious metals and critical materials. Its brand matters in a niche where trust drives flows. Revenue is cyclical with commodity sentiment, but margins are attractive when flows turn. Unlike broad asset managers, Sprott doesn’t pretend to be everything to everyone. Capital-light operations support strong free cash flow. Product innovation keeps the platform relevant. This is not a stable annuity — it’s a levered play on investor appetite for real assets. When sentiment shifts, Sprott moves fast.

Pitch Summary:
We also added Heidelberg Materials, a German supplier of building materials. The company could see upside to margins from improving capacity utilization in Europe and its advantages in implementing decarbonization technologies in the production of cement. European construction activity is at depressed levels, paving the way for a recovery driven by German and broader EU stimulus.

BSD Analysis:
Heidelberg Materials controls irreplaceable cement and aggregates assets that underpin global infrastructure and construction. This is a brutally heavy industry, but pricing discipline has improved, allowing margins to hold even as volumes fluctuate. Decarbonization is no longer just a cost — it’s a competitive moat as smaller players fall away. Cash flow is strong because assets are long-lived and locally dominant. Infrastructure spending and reshoring trends provide structural demand. Capital allocation has become more shareholder-friendly than in the past. The stock trades like a pure cyclical, but the business increasingly behaves like infrastructure. When cycles turn, Heidelberg snaps back quickly. This is industrial muscle with improving discipline.